Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Replicel Life Sciences Inc
(TSV:
RP
)
N/A
UNCHANGED
Last Price
Updated: 3:56 PM EDT, Mar 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
0.0400 (70)
Ask (Size)
0.1500 (620)
Prev. Close
0.0550
Today's Range
N/A - N/A
52wk Range
0.0500 - 0.1450
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
RealPage Announces Strategic Partnership with Habitat for Humanity International to Build Housing in Local Communities
December 14, 2023
From
RealPage, Inc.
Via
Business Wire
RealPage Accelerates the Pace of Innovation for Multifamily with Market-Leading AI-Enabled Front Office Suite
November 15, 2023
From
RealPage, Inc.
Via
Business Wire
Performance
More News
Read More
RealPage Unveils New Multifamily Rental Trends
August 08, 2023
From
RealPage
Via
Business Wire
RepliCel Provides Corporate Update
November 28, 2022
Via
ACCESSWIRE
RepliCel Announces Material Patent Milestones in Key Markets
August 04, 2022
Via
ACCESSWIRE
RealPage Awarded 2023 ENERGY STAR Partner of the Year for Sustained Excellence
March 28, 2023
From
RealPage
Via
Business Wire
Key Cannabis Exec Changes You Need To Know About: Curaleaf Names Director Of Social Equity & More Industry Appointments
December 09, 2022
Via
Benzinga
Grabbing Opportunity In Texas Migration Numbers, Rental Fund Buys Dallas-Area Single-Family Home Development
August 18, 2022
Via
Benzinga
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
August 02, 2022
Via
ACCESSWIRE
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
Via
ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
Via
ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
Via
ACCESSWIRE
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Material Patent Milestones
January 10, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
RepliCel Closed Final Tranche of Strategic Investment Commitment
December 21, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Terminates License Agreement with Shiseido
December 21, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RealPage Agrees to Acquire HomeWiseDocs, The Premier Provider of Disclosure Management Services to the Community Association Industry
December 07, 2021
From
RealPage, Inc.
Via
Business Wire
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
November 11, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
November 09, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
October 28, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Dermal Injector Update
October 27, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
October 18, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
October 12, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Economy
Exposures
Economy
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.